Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage clinical trial published in The Lancent. The interim analysis of the Phase 3 trial of Sputnik V vaccine showed 916% efficacy against Covid-19 and was well tolerated in a large cohort, The Lancent review states. From 21 days after the first dose of vaccine in the trial, 16 of 14,964 participants in the vaccine group and 62 of 4,902 in the placebo group were confirmed to have Covid-19. The vaccine efficacy was 91.6%, they investigators write. In September 2020, Dr. Reddy’s Laboratories (RDY) partnered with Russian Direct Investment Fund o conduct the clinical trials of the Sputnik V vaccine and for its distribution rights in India. Shares of Dr. Reddy’s are up 2% to $60.11 in premarket trading. Barclays this morning upgraded the shares to Overweight citing upside from the Sputnik V vaccine.